Biogen Revenue 2010-2022 | BIIB

Biogen annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Biogen revenue for the quarter ending September 30, 2022 was $2.509B, a 9.73% decline year-over-year.
  • Biogen revenue for the twelve months ending September 30, 2022 was $10.363B, a 6.64% decline year-over-year.
  • Biogen annual revenue for 2021 was $10.982B, a 18.32% decline from 2020.
  • Biogen annual revenue for 2020 was $13.445B, a 6.49% decline from 2019.
  • Biogen annual revenue for 2019 was $14.378B, a 6.88% increase from 2018.
Biogen Annual Revenue
(Millions of US $)
2021 $10,982
2020 $13,445
2019 $14,378
2018 $13,453
2017 $12,274
2016 $11,449
2015 $10,764
2014 $9,703
2013 $6,932
2012 $5,516
2011 $5,049
2010 $4,716
2009 $4,377
Biogen Quarterly Revenue
(Millions of US $)
2022-09-30 $2,509
2022-06-30 $2,589
2022-03-31 $2,532
2021-12-31 $2,734
2021-09-30 $2,779
2021-06-30 $2,775
2021-03-31 $2,694
2020-12-31 $2,853
2020-09-30 $3,376
2020-06-30 $3,682
2020-03-31 $3,534
2019-12-31 $3,671
2019-09-30 $3,600
2019-06-30 $3,617
2019-03-31 $3,490
2018-12-31 $3,526
2018-09-30 $3,439
2018-06-30 $3,357
2018-03-31 $3,131
2017-12-31 $3,307
2017-09-30 $3,078
2017-06-30 $3,078
2017-03-31 $2,811
2016-12-31 $2,872
2016-09-30 $2,956
2016-06-30 $2,894
2016-03-31 $2,727
2015-12-31 $2,839
2015-09-30 $2,778
2015-06-30 $2,592
2015-03-31 $2,555
2014-12-31 $2,641
2014-09-30 $2,511
2014-06-30 $2,421
2014-03-31 $2,130
2013-12-31 $1,966
2013-09-30 $1,828
2013-06-30 $1,723
2013-03-31 $1,415
2012-12-31 $1,418
2012-09-30 $1,386
2012-06-30 $1,421
2012-03-31 $1,292
2011-12-31 $1,327
2011-09-30 $1,310
2011-06-30 $1,209
2011-03-31 $1,203
2010-12-31 $1,219
2010-09-30 $1,176
2010-06-30 $1,213
2010-03-31 $1,109
2009-12-31 $1,127
2009-09-30 $1,121
2009-06-30 $1,093
2009-03-31 $1,036
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $42.097B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00